180 related articles for article (PubMed ID: 31905966)
81. Focal adhesion kinase: from biological functions to therapeutic strategies.
Tan X; Yan Y; Song B; Zhu S; Mei Q; Wu K
Exp Hematol Oncol; 2023 Sep; 12(1):83. PubMed ID: 37749625
[TBL] [Abstract][Full Text] [Related]
82. Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.
Kumar S; Chatterjee M; Ghosh P; Ganguly KK; Basu M; Ghosh MK
Genes Dis; 2023 Jul; 10(4):1318-1350. PubMed ID: 37397537
[TBL] [Abstract][Full Text] [Related]
83. Biomarkers of disease recurrence in stage I testicular germ cell tumours.
Lesko P; Chovanec M; Mego M
Nat Rev Urol; 2022 Nov; 19(11):637-658. PubMed ID: 36028719
[TBL] [Abstract][Full Text] [Related]
84. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.
Sun J; Li X; Chen P; Gao Y
J Inflamm Res; 2022; 15():4061-4085. PubMed ID: 35873388
[TBL] [Abstract][Full Text] [Related]
85. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model.
Wei Y; Wang Y; Liu N; Qi R; Xu Y; Li K; Feng Y; Shi B
Front Pharmacol; 2021; 12():820446. PubMed ID: 35115949
[TBL] [Abstract][Full Text] [Related]
86. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.
Fan Y; He S
Cancer Manag Res; 2022; 14():1-17. PubMed ID: 35018117
[TBL] [Abstract][Full Text] [Related]
87. FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer.
Shiau JP; Wu CC; Chang SJ; Pan MR; Liu W; Ou-Yang F; Chen FM; Hou MF; Shih SL; Luo CW
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944605
[TBL] [Abstract][Full Text] [Related]
88. Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771753
[TBL] [Abstract][Full Text] [Related]
89. High nuclear expression of APE1 correlates with unfavorable prognosis and promotes tumor growth in hepatocellular carcinoma.
Lu X; Zhao H; Yuan H; Chu Y; Zhu X
J Mol Histol; 2021 Apr; 52(2):219-231. PubMed ID: 33392892
[TBL] [Abstract][Full Text] [Related]
90. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
Li C; Yao H; Wang H; Fang JY; Xu J
Oncogene; 2021 Feb; 40(6):1128-1146. PubMed ID: 33323966
[TBL] [Abstract][Full Text] [Related]
91. Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.
Wińska P; Karatsai O; Staniszewska M; Koronkiewicz M; Chojnacki K; Rędowicz MJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872257
[TBL] [Abstract][Full Text] [Related]
92. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
[TBL] [Abstract][Full Text] [Related]
93. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
94. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
95. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
96. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
97. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
98. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905966
[TBL] [Abstract][Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
